Search Within

Department of Medicine

Formats
  1. Journal Article (19579)
  2. Meeting Abstract (16038)
  3. Review (1149)
  4. Book Section (934)
  5. Editorial (607)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (235)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22314)
  2. Hematologic Malignancies, Division of (13268)
  3. Center for Hematologic Malignancies (11053)
  4. GSK Faculty (10642)
  5. Survivorship Research (9326)
  6. Division of Subspecialty Medicine (7533)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1068)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1052)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3721)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6457)
  2. Elsevier Inc. (4215)
  3. American Society of Hematology (4000)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2110)

More Publishers

Results (39603)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2− early breast cancer: A United States Electronic Health Records database analysis
    Journal Article

    Tarantino, P.; Rugo, H. S.; Curigliano, G.; O'Shaughnessy, J. A.; Janni, W.; Jhaveri, K.; Mouabbi, J.; Brufsky, A.; Hamilton, E.; O'Regan, R.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma
    Journal Article

    Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N. M.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)
    Journal Article

    Naughton, M. J.; Zahrieh, D. M.; Gnant, M.; Zdenkowski, N.; Lemieux, J.; Mao, J. J.; Bjelic-Radisic, V.; Shinn, E.; Balic, M.; Thomssen, C.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • Improving urinary tract infection diagnostics in oncology: Reliability of reflex urine culture in immunosuppressed neutropenic and non-neutropenic cancer patients
    Journal Article

    Laracy, J. C.; Chan, J. L.; Kodama, R.; Yan, J.; Raible, K. M.; Sepkowitz, K.; McVoy, L.; Babady, N. E.; Kamboj, M.
    Clinical Infectious Diseases (2025)

    Fulltext@MSK | Save
  • Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non-small cell lung cancer
    Journal Article

    Pecci, F.; Thummalapalli, R.; Alden, S. L.; Ricciuti, B.; Alessi, J. V.; Elkrief, A.; Rizvi, H.; Wang, X.; Jeng, M.; Egger, J. V.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • A phase I study of FHD-286, a dual BRG1/BRM (SMARCA4/SMARCA2) inhibitor, in patients with advanced myeloid malignancies
    Journal Article

    DiNardo, C. D.; Fathi, A. T.; Kishtagari, A.; Bhalla, K. N.; Quintás-Cardama, A.; Reilly, S. A.; Almon, C.; Patriquin, C.; Nabhan, S.; Healy, K.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma
    Journal Article

    Tap, W. D.; Cote, G. M.; Burris, H.; Gore, L.; Elias, A.; Beeram, M.; Conley, A. P.; Gianolio, D. A.; Qu, Z.; Pandya, S.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Longitudinal genomic analysis to fine-tune targeted therapy: Results of the phase II LOGIC 2 trial in patients with BRAF(V600)-mutant metastatic melanoma
    Journal Article

    Dummer, R.; Sandhu, S.; Miller, W. H. Jr; Butler, M. O.; Taylor, M. H.; Heinzerling, L.; Blank, C. U.; Muñoz-Couselo, E.; Burris, H. A. 3rd; Postow, M. A.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade
    Journal Article

    Blanchard, L.; Vina, E.; Ljubetic, J.; Meneur, C.; Tarroux, D.; Baez, M.; Marino, A.; Ortega, N.; Knorr, D. A.; Ravetch, J. V.; more...
    Cell Reports Medicine (2025)

    Fulltext@MSK | Save
  • A phase II study of fulvestrant plus abemaciclib in hormone receptor–positive advanced or recurrent endometrial cancer
    Journal Article

    Green, A. K.; Zhou, Q.; Iasonos, A.; Zammarrelli, W. A. 3rd; Weigelt, B.; Ellenson, L. H.; Chhetri-Long, R.; Shah, P.; Loh, J.; Hom, V.; more...
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save